Liraglutide: Uses, Dosage & Side Effects
A GLP-1 receptor agonist for type 2 diabetes and chronic weight management, administered once daily by subcutaneous injection
Liraglutide is a GLP-1 receptor agonist (incretin mimetic) used for the treatment of type 2 diabetes mellitus and chronic weight management. It is a once-daily injectable medication that mimics the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1), stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. At lower doses (up to 1.8 mg), liraglutide is marketed under the brand name Victoza for diabetes treatment; at the higher dose of 3.0 mg (Saxenda), it is approved for obesity management. The landmark LEADER trial demonstrated significant cardiovascular benefits in patients with type 2 diabetes at high cardiovascular risk. Liraglutide requires a prescription and is listed on the WHO Model List of Essential Medicines.
Quick Facts: Liraglutide
Key Takeaways
- Liraglutide is a once-daily subcutaneous injection that lowers blood glucose by stimulating insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia when used alone.
- At doses up to 1.8 mg daily (Victoza), it treats type 2 diabetes; at 3.0 mg daily (Saxenda), it is approved for chronic weight management in adults with obesity or overweight with comorbidities.
- The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with type 2 diabetes at high cardiovascular risk.
- The most common side effects are gastrointestinal (nausea, diarrhea, vomiting), which typically diminish over time; gradual dose escalation over several weeks helps minimize these effects.
- Liraglutide should not be used in type 1 diabetes, diabetic ketoacidosis, or in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What Is Liraglutide and What Is It Used For?
Liraglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a hormone naturally produced by L-cells in the small intestine in response to food intake. The native GLP-1 hormone has a very short half-life of approximately 1–2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Liraglutide was engineered to overcome this limitation through two key modifications: a fatty acid side chain (palmitic acid) attached via a glutamic acid spacer to lysine at position 26, and the substitution of arginine for lysine at position 34. These modifications allow liraglutide to bind reversibly to serum albumin, resulting in a plasma half-life of approximately 13 hours, making it suitable for once-daily administration.
The medication shares 97% amino acid sequence homology with endogenous human GLP-1, ensuring high receptor affinity and specificity. When liraglutide activates the GLP-1 receptor on pancreatic beta cells, it enhances glucose-dependent insulin secretion — meaning insulin is released primarily when blood glucose levels are elevated. This glucose-dependent mechanism is fundamentally important because it greatly reduces the risk of hypoglycemia compared with sulfonylureas or exogenous insulin therapy. Simultaneously, liraglutide suppresses inappropriate glucagon secretion from pancreatic alpha cells, which is often elevated in patients with type 2 diabetes and contributes to hyperglycemia.
Beyond its effects on pancreatic hormones, liraglutide has significant extrapancreatic actions that contribute to its therapeutic profile. It slows gastric emptying, which helps blunt postprandial (after-meal) glucose excursions and contributes to feelings of fullness. Importantly, liraglutide acts on appetite-regulating centres in the hypothalamus, promoting satiety and reducing food intake. These effects on appetite and gastric motility explain why liraglutide is associated with clinically meaningful weight loss, a particularly valuable property in the management of type 2 diabetes where most patients are overweight or obese.
For the treatment of type 2 diabetes mellitus, liraglutide (marketed as Victoza) is used at doses of up to 1.8 mg once daily. It can be prescribed as monotherapy when metformin is contraindicated or not tolerated, or in combination with other antidiabetic medications including metformin, pioglitazone, sulfonylureas, sodium-glucose co-transporter 2 inhibitors (SGLT2i), and insulin. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend GLP-1 receptor agonists as preferred second-line agents after metformin, particularly in patients with established cardiovascular disease or at high cardiovascular risk, based on the results of the landmark LEADER trial.
At the higher dose of 3.0 mg once daily (marketed as Saxenda), liraglutide is approved for chronic weight management as an adjunct to reduced-calorie diet and increased physical activity in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Clinical trials have shown that liraglutide 3.0 mg produces an average weight loss of approximately 5–8% of initial body weight when combined with lifestyle modifications. Victoza and Saxenda should not be used together, as they contain the same active ingredient.
What Should You Know Before Taking Liraglutide?
Contraindications
There are specific situations where liraglutide must not be used. Understanding these contraindications is essential for ensuring safe medication use and preventing serious adverse events. You should not use liraglutide if any of the following apply:
- Allergy to liraglutide: Known hypersensitivity to liraglutide or any of the excipients in the formulation (disodium phosphate dihydrate, propylene glycol, phenol, sodium hydroxide, hydrochloric acid, water for injections).
- Type 1 diabetes: Liraglutide is not insulin and must not be used in patients with type 1 diabetes, as their bodies do not produce insulin. It cannot replace insulin therapy.
- Diabetic ketoacidosis: This medication should not be used for the treatment of diabetic ketoacidosis (DKA), a serious complication of diabetes characterised by high blood glucose, ketone accumulation, and metabolic acidosis.
- Medullary thyroid carcinoma (MTC): In the United States, liraglutide carries a boxed warning regarding thyroid C-cell tumours based on preclinical findings in rodents. It is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Warnings and Precautions
Before starting liraglutide, inform your healthcare provider about your complete medical history. The following conditions require special caution and careful monitoring:
- Pancreatic disease: Use with caution in patients with a history of pancreatitis. An alternative antidiabetic therapy should be considered.
- Thyroid disease: Patients with thyroid disease, including thyroid nodules and thyroid enlargement, should consult their doctor before use. Cases of thyroid adverse events including increased calcitonin levels, goitre, and thyroid neoplasms have been reported.
- Severe kidney disease: There is limited experience with liraglutide in patients with severe renal impairment (eGFR below 15 mL/min/1.73 m²) or on dialysis. Use is not recommended in these patients.
- Severe liver disease: Liraglutide is not recommended in patients with severe hepatic impairment due to lack of therapeutic experience.
- Severe heart failure: Liraglutide is not recommended in patients with New York Heart Association (NYHA) class IV heart failure due to limited clinical experience.
- Gastroparesis or inflammatory bowel disease: Liraglutide slows gastric emptying and is not recommended in patients with severe gastroparesis or inflammatory bowel disease.
- Dehydration: Gastrointestinal side effects (nausea, vomiting, diarrhea) may cause dehydration, which could in rare cases lead to reduced kidney function. It is important to drink adequate fluids, especially during the initial weeks of treatment.
Pregnancy and Breastfeeding
Liraglutide should not be used during pregnancy. If you are pregnant, think you may be pregnant, or are planning to have a baby, tell your doctor before using this medication. Animal studies have shown reproductive toxicity, and the potential risk to a human foetus is not known. Women of childbearing potential should use effective contraception during treatment.
It is not known whether liraglutide passes into breast milk. Due to the lack of data, liraglutide should not be used during breastfeeding. Consult your doctor if you are breastfeeding or planning to breastfeed.
Children and Adolescents
For the diabetes indication, liraglutide can be used in adolescents and children from 10 years of age. No data are available for children under 10 years. For the weight management indication (Saxenda 3.0 mg), it has been studied in adolescents aged 12–17 years. Dosing in paediatric populations should be supervised by a specialist.
Driving and Using Machines
When liraglutide is used in combination with a sulfonylurea or insulin, low blood sugar (hypoglycemia) may occur, which can impair your concentration and reaction time. If you experience signs of low blood sugar, do not drive or operate machinery until the episode has resolved. Discuss with your doctor whether it is safe for you to drive, particularly if your treatment regimen includes medications known to cause hypoglycemia.
How Does Liraglutide Interact with Other Drugs?
Because liraglutide slows gastric emptying, it has the potential to affect the rate of absorption (but generally not the overall extent of absorption) of concomitantly administered oral medications. Clinical pharmacokinetic studies have not demonstrated any clinically significant drug interactions that require dose adjustments, but caution is warranted with narrow therapeutic index drugs. Always inform your healthcare provider about all medications, supplements, and herbal remedies you are taking.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Sulfonylureas (glimepiride, glibenclamide, glipizide) | Significantly increased risk of hypoglycemia due to combined insulin-stimulating effects | Your doctor may need to reduce the sulfonylurea dose when starting liraglutide. Monitor blood glucose more frequently. |
| Insulin (all types) | Increased risk of hypoglycemia and potential risk of hyperglycemia/DKA if insulin is reduced too much | Insulin dose reduction is usually necessary. Your doctor will advise on dose adjustment and recommend more frequent blood glucose monitoring. |
| Warfarin and other oral anticoagulants | Delayed gastric emptying may affect absorption timing; changes in INR have been reported | More frequent INR/coagulation monitoring is recommended, especially when starting or stopping liraglutide. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Metformin | No clinically significant pharmacokinetic interaction; commonly used together | Safe combination; no dose adjustment needed for metformin. |
| Paracetamol (Acetaminophen) | Delayed absorption (peak concentration delayed by approximately 1 hour) but total absorption unchanged | No dose adjustment required. Be aware of slight delay in onset of pain relief. |
| Oral contraceptives | Slight delay in absorption due to slowed gastric emptying; overall bioavailability not affected | No dose adjustment required. Contraceptive efficacy is maintained. |
| Atorvastatin | Slight delay in absorption; total exposure unchanged | No dose adjustment needed. |
| Digoxin | Slight delay in time to peak concentration; overall exposure unchanged | No dose adjustment required, but monitor as digoxin has a narrow therapeutic index. |
What Is the Correct Dosage of Liraglutide?
Adults — Type 2 Diabetes (Victoza)
Dose Titration Schedule
Liraglutide is started at a low dose and gradually increased to minimise gastrointestinal side effects:
- Week 1–2: 0.6 mg once daily (starting dose — not a therapeutic dose for blood glucose control)
- Week 3 onwards: 1.2 mg once daily (standard maintenance dose)
- If needed: Increase to 1.8 mg once daily (maximum dose for diabetes) after at least one week at 1.2 mg, if blood glucose control is insufficient
Dose changes should only be made under the supervision of your prescribing physician. Do not increase or decrease the dose without medical advice.
Adults — Chronic Weight Management (Saxenda)
- Week 1: 0.6 mg once daily
- Week 2: 1.2 mg once daily
- Week 3: 1.8 mg once daily
- Week 4: 2.4 mg once daily
- Week 5 onwards: 3.0 mg once daily (maintenance dose)
Treatment should be discontinued if at least 5% weight loss has not been achieved after 12 weeks at the 3.0 mg dose.
Children and Adolescents
Type 2 Diabetes — Ages 10 and Older
The dose titration schedule is the same as for adults: starting at 0.6 mg once daily, increasing to 1.2 mg, and up to a maximum of 1.8 mg based on glycaemic response and tolerability. Treatment should be under specialist supervision. There is no data available for children under 10 years of age.
Elderly Patients
No dose adjustment is required based on age alone. However, therapeutic experience in patients aged 75 years and above is limited. Liraglutide should be used with caution in this population, and dose escalation should be based on individual clinical response and tolerability. Kidney function should be monitored, as elderly patients are more likely to have renal impairment.
How to Inject Liraglutide
Liraglutide is supplied in a pre-filled, multi-dose injection pen. Each pen contains 18 mg of liraglutide in 3 mL solution. Your doctor, pharmacist, or nurse will show you how to use the pen before your first injection. Key points to remember:
- Injection sites: The front of the thighs, the abdomen (stomach area), or the upper arm. Rotate your injection site daily to reduce the risk of developing lumps under the skin (cutaneous amyloidosis).
- Route: Subcutaneous injection only. Never inject into a vein or muscle.
- Timing: Once daily at any time of day, regardless of meals. Once you find a convenient time, try to inject at approximately the same time each day.
- Needles: Injection needles are not included with the pen. Use compatible pen needles as recommended by your healthcare provider.
- Pen cap: Always replace the pen cap after use. The solution is light-sensitive.
Missed Dose
If you miss a dose of liraglutide, take it as soon as you remember. However, if more than 12 hours have passed since your usual dosing time, skip the missed dose and take your next dose at the regular scheduled time the following day. Do not take a double dose or increase the dose to compensate for the missed injection.
Overdose
If you accidentally inject more liraglutide than prescribed, contact your doctor, hospital, or poison control centre immediately. An overdose may cause severe nausea, vomiting, diarrhoea, and hypoglycemia (low blood sugar). Treatment is supportive and should be based on the patient's clinical signs and symptoms. There is no specific antidote for liraglutide.
What Are the Side Effects of Liraglutide?
Like all medicines, liraglutide can cause side effects, although not everybody gets them. The following section summarises side effects by frequency, based on data from clinical trials and post-marketing surveillance. If you experience any side effects that concern you, consult your healthcare provider. It is particularly important to be aware of the warning signs of serious side effects such as pancreatitis and severe allergic reactions.
Very Common
May affect more than 1 in 10 people
- Nausea (feeling sick) — usually improves over time
- Diarrhoea — usually improves over time
Common
May affect up to 1 in 10 people
- Hypoglycemia (low blood sugar) — especially when used with sulfonylureas or insulin
- Vomiting
- Headache
- Indigestion (dyspepsia)
- Gastritis (inflammation of the stomach lining)
- Gastroesophageal reflux disease (GERD/heartburn)
- Abdominal pain or discomfort
- Abdominal bloating
- Constipation
- Flatulence (gas)
- Decreased appetite
- Bronchitis
- Common cold (nasopharyngitis)
- Dizziness
- Increased heart rate
- Fatigue
- Toothache
- Injection site reactions (bruising, pain, irritation, itching, rash)
- Increased pancreatic enzymes (lipase, amylase)
Uncommon
May affect up to 1 in 100 people
- Allergic reactions such as urticaria (hives) and pruritus (itching)
- Dehydration, sometimes with reduced kidney function
- General malaise (feeling unwell)
- Gallstones (cholelithiasis)
- Inflammation of the gallbladder (cholecystitis)
- Altered taste (dysgeusia)
- Delayed gastric emptying
Rare
May affect up to 1 in 1,000 people
- Severe allergic reaction (anaphylaxis) with breathing difficulty, facial/throat swelling, rapid heartbeat
- Intestinal obstruction (a severe form of constipation with abdominal pain, bloating, vomiting)
Very Rare
May affect up to 1 in 10,000 people
- Acute pancreatitis (inflammation of the pancreas) — a potentially life-threatening condition. Symptoms: severe, persistent abdominal pain radiating to the back, nausea, vomiting. Stop liraglutide and seek medical attention immediately.
Signs of Low Blood Sugar (Hypoglycemia)
Hypoglycemia is more likely when liraglutide is used together with a sulfonylurea or insulin. Warning signs can appear suddenly and may include: cold sweats, pale and cold skin, headache, rapid heartbeat, nausea, excessive hunger, visual disturbances, drowsiness, weakness, nervousness, anxiety, confusion, difficulty concentrating, and trembling. Your doctor will tell you how to treat low blood sugar and what to do if you notice warning signs. They may reduce your sulfonylurea or insulin dose before you start liraglutide.
How Should You Store Liraglutide?
Proper storage is essential to ensure the medication remains effective and safe to use. Liraglutide solution should be clear and colourless or almost colourless. Do not use it if the solution appears cloudy, discoloured, or contains particles.
Before First Use (Unopened)
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F)
- Do not freeze. Do not store near the freezer compartment.
- Keep in the original packaging to protect from light
- Check the expiry date on the pen label and carton (the last day of the stated month)
After First Use (In-Use)
- Can be stored for up to 30 days at room temperature (not exceeding 30°C / 86°F) or in the refrigerator (2°C–8°C)
- Do not freeze
- Always replace the pen cap after each injection (light-sensitive)
- Discard 30 days after first use, even if solution remains in the pen
Keep this medicine out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use, in accordance with local regulations. These measures help to protect the environment.
What Does Liraglutide Contain?
Active Ingredient
The active substance is liraglutide. Each 1 mL of injection solution contains 6 mg of liraglutide. One pre-filled injection pen contains 18 mg of liraglutide in 3 mL of solution. Liraglutide is a recombinant human GLP-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae (baker’s yeast).
Inactive Ingredients (Excipients)
| Excipient | Function |
|---|---|
| Disodium phosphate dihydrate | Buffer (pH stabilisation) |
| Propylene glycol (E1520) | Tonicity agent |
| Phenol | Preservative |
| Sodium hydroxide | pH adjustment |
| Hydrochloric acid (concentrated) | pH adjustment |
| Water for injections | Solvent |
This medicine contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free.
Packaging
Liraglutide is supplied as a clear, colourless solution in a type I glass cartridge with a bromobutyl rubber piston, assembled in a pre-filled injection pen. Pens are available in packs of 1, 2, 3, 5, or 10 pens. Not all pack sizes may be marketed in all countries. Injection needles are not included and must be purchased separately.
Frequently Asked Questions About Liraglutide
Liraglutide is a GLP-1 receptor agonist used primarily for the treatment of type 2 diabetes mellitus (marketed as Victoza at doses up to 1.8 mg daily). It helps lower blood glucose levels by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite. At a higher dose of 3.0 mg daily, liraglutide is also approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities (marketed as Saxenda). Additionally, the LEADER cardiovascular outcomes trial demonstrated significant cardiovascular benefits in patients with type 2 diabetes at high cardiovascular risk.
The most common side effects of liraglutide are gastrointestinal: nausea, diarrhea, and vomiting. These typically occur during the initial weeks of treatment and tend to diminish over time as the body adapts. Other common side effects include headache, decreased appetite, indigestion, constipation, dizziness, increased heart rate, and injection site reactions. Hypoglycemia (low blood sugar) can occur when liraglutide is combined with sulfonylureas or insulin. Gradual dose escalation helps minimize gastrointestinal side effects.
Liraglutide is injected subcutaneously (under the skin) once daily at any time of day, regardless of meals. The best injection sites are the front of the thigh, the abdomen (stomach area), or the upper arm. You should rotate your injection site each day to reduce the risk of developing lumps under the skin. Do not inject into a vein or muscle. The pre-filled pen allows you to dial your prescribed dose. Once you establish a convenient injection time, try to inject at approximately the same time each day. Your healthcare provider will demonstrate the injection technique before your first use.
Cases of acute pancreatitis (inflammation of the pancreas) have been reported with liraglutide use, although this is classified as a very rare side effect (fewer than 1 in 10,000 patients). Pancreatitis can be a serious and potentially life-threatening condition. If you experience severe, persistent abdominal pain that may radiate to the back, accompanied by nausea and vomiting, you should stop taking liraglutide and seek immediate medical attention. Patients with a history of pancreatitis should use liraglutide with caution, and an alternative treatment may be considered.
Both Victoza and Saxenda contain the same active ingredient, liraglutide, but they are approved for different indications and used at different doses. Victoza is prescribed for type 2 diabetes at doses of 0.6 mg, 1.2 mg, or 1.8 mg once daily. Saxenda is approved for chronic weight management (obesity treatment) at a dose of 3.0 mg once daily in adults with a BMI of 30 or above, or 27 or above with weight-related comorbidities. They should not be used together, and neither should be combined with other GLP-1 receptor agonists.
Yes, liraglutide is associated with clinically significant weight loss. At diabetes doses (1.2–1.8 mg), patients typically experience a modest weight reduction of 2–3 kg. At the weight management dose (3.0 mg, Saxenda), clinical trials demonstrated an average weight loss of approximately 5–8% of initial body weight when combined with lifestyle modifications (reduced-calorie diet and increased physical activity). This weight loss effect is primarily due to liraglutide's actions on appetite centres in the brain, promoting feelings of satiety and reducing food intake, as well as slowing gastric emptying.
References
This article is based on the following evidence-based sources. All medical claims adhere to Evidence Level 1A, the highest quality of evidence based on systematic reviews and randomised controlled trials.
- European Medicines Agency (EMA). Summary of Product Characteristics — Victoza (liraglutide). Last updated 2025. Available from: EMA — Victoza.
- U.S. Food and Drug Administration (FDA). Prescribing Information — Victoza (liraglutide) injection. Reference ID: 4859012.
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER Trial). New England Journal of Medicine. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827.
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1).
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786.
- World Health Organization (WHO). Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. Last updated 2022.
- European Medicines Agency (EMA). Summary of Product Characteristics — Saxenda (liraglutide 3.0 mg). Last updated 2025.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006;368(9548):1696–1705.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, clinical pharmacology, and internal medicine. Our team follows strict editorial standards based on the GRADE evidence framework, ensuring that all medical information is accurate, up-to-date, and based on the highest quality of evidence available.
Last medical review: | Next scheduled review:
If you notice any inaccuracies or have suggestions for improvement, please contact our editorial team.